TEK and neoplasm: Serum levels of Tie-2, a biomarker for VEGF inhibition29, stainings for the endothelial cell marker CD31 and CD31+ vessel counts on primary tumor sections corroborated these VEGF results with significant reduction upon cisplatin treatment (Figs. 3c and 4).